

# Data deficits around Covaxin contribute to vaccine hesitancy in India | First Draft

By Ali Abbas Ahmadi

March 3, 2021

The world's biggest Covid-19 vaccination drive is underway in India, with the ambitious goal of vaccinating 300 million people by July. This has been met with [a wave of vaccine hesitancy](#) as doubts around Covaxin — [approved by New Delhi](#) in January along with the Oxford/AstraZeneca vaccine, known in India as [Covishield](#) — continue to spread.

Covaxin was developed locally by Indian vaccine maker Bharat Biotech. Although information around Phase 1 trials was published in [The Lancet](#), [Phase 3 trials](#) are still underway.

The lack of published data around Covaxin's development in some ways mirrors AstraZeneca's failure at first [to publicly disclose](#) a dosing error that saw higher efficacy rates among participants who received a half first dose, sowing public doubt about the vaccine.

[...]

Source: [Data deficits around Covaxin contribute to vaccine hesitancy in India](#)